tacrolimus (ALS Therapy Development Institute)

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug Nametacrolimus (ALS Therapy Development Institute)
Drug Alias NameFK-506 (ALS Therapy Development Institute)tacrolimusTDI-0114
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuroprotectantsImmunomodulatorsCalcineurin inhibitors
TargetsCalcineurin
Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesAmyotrophic Lateral Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesALS Therapy Development Foundation Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesALS Therapy Development Foundation Inc
Active IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A